Literature DB >> 3316307

Blood protein binding of cyclosporine in transplant patients.

I Zaghloul1, R J Ptachcinski, G J Burckart, D Van Thiel, T E Starzel, R Venkataramanan.   

Abstract

The objective of this study was to compare the binding of cyclosporine to blood proteins between four healthy subjects and five liver and eight renal transplant patients. Fresh heparinized blood was obtained, to which sufficient quantities of tritium-labelled cyclosporine and unlabelled cyclosporine were added to blood samples or red blood cell (RBC) suspensions. Concentrations of cyclosporine in whole blood, plasma, RBC suspension, and phosphate buffer were estimated by liquid scintigraphy. The blood:plasma ratio of cyclosporine in transplant patients was significantly lower (P less than .05) than that in healthy volunteers. The RBC:buffer ratio, a measure of affinity of RBCs for cyclosporine, was highest in those with liver transplants and lowest in those with kidney transplants. The unbound fraction of cyclosporine in plasma was less in transplant patients than in healthy volunteers. The results of this study indicate that there are differences in blood protein binding of cyclosporine between transplant patients that may contribute to the differences in the pharmacokinetics and pharmacodynamics of this drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316307      PMCID: PMC2964269          DOI: 10.1002/j.1552-4604.1987.tb02192.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Combined hyperlipidemia and hypertriglyceridemia in renal allograft recipients. Comparison with non-renal combined hyperlipidemic or hypertriglyceridemic patients and normal subjects.

Authors:  J B Somer; L K Abbott; J M Aitken; C Elliott
Journal:  Clin Chim Acta       Date:  1979-10-01       Impact factor: 3.786

2.  High-density lipoprotein in chronic renal failure and after renal transplantation.

Authors:  E Savdie; J C Gibson; J H Stewart; L A Simons
Journal:  Br Med J       Date:  1979-04-07

Review 3.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

4.  Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol.

Authors:  E R Garrett; C A Hunt
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

5.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

6.  Comparison of the erythrocyte partitioning method with two classical methods for estimating free drug fraction in plasma.

Authors:  A H Trung; G Sirois; L M Dubé; I J McGilveray
Journal:  Biopharm Drug Dispos       Date:  1984 Jul-Sep       Impact factor: 1.627

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients.

Authors:  T G Rosano
Journal:  Clin Chem       Date:  1985-03       Impact factor: 8.327

  8 in total
  10 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  The binding of cyclosporin A to human plasma: an in vitro microdialysis study.

Authors:  H Yang; W F Elmquist
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

3.  Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.

Authors:  Sarah Billington; Steven Shoner; Scott Lee; Kindra Clark-Snustad; Matthew Pennington; David Lewis; Mark Muzi; Shirley Rene; Jean Lee; Tot Bui Nguyen; Vineet Kumar; Kazuya Ishida; Laigao Chen; Xiaoyan Chu; Yurong Lai; Laurent Salphati; Cornelis E C A Hop; Guangqing Xiao; Mingxiang Liao; Jashvant D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

Review 4.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  Characterization of cyclosporine A uptake in human erythrocytes.

Authors:  C Reichel; M von Falkenhausen; D Brockmeier; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient.

Authors:  Hanene Eljebari; Emna Gaies; Nadia Ben Fradj; Nadia Jebabli; Issam Salouage; Sameh Trabelsi; Mohamed Lakhal; Anis Klouz
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

Review 7.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

Review 9.  Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.

Authors:  Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

10.  Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.

Authors:  Tatsuki Mochizuki; Yasunori Aoki; Takashi Yoshikado; Kenta Yoshida; Yurong Lai; Hideki Hirabayashi; Yoshiyuki Yamaura; Kevin Rockich; Kunal Taskar; Tadayuki Takashima; Xiaoyan Chu; Maciej J Zamek-Gliszczynski; Jialin Mao; Kazuya Maeda; Kenichi Furihata; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Clin Transl Sci       Date:  2022-05-02       Impact factor: 4.438

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.